United Kingdom

People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

17 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kasinger, James 

Mr. Jim Kasinger serves as General Counsel and Secretary to the Board of Directors at CRISPR Therapeutics Ltd. He has nearly 20 years of experience advising and counseling private and public companies in the biotechnology and technology sectors. Prior to joining the Company, he was the General Counsel and Secretary of Moderna Therapeutics, a Cambridge-based biotechnology company, where, among other things, he helped lead two equity financings and several collaborations including with AZ, Merck and Vertex. Before that, he was the General Counsel at PlumChoice, Inc., a provider of technical support services to Fortune 1000 companies. Before going in-house, he was a partner in the Business Practice Group at the global law firm, Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies in all stages of their life cycles, from formation, to obtaining seed and growth financings, to initial public offering, merger or sale. He started his legal career as an associate at Testa, Hurwitz & Thibeault. He received his J.D. from Boston College Law School, graduating cum laude, and a B.A. from Wheaton College, graduating magna cum laude.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --